http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102227422-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5af569acbf26227d89205abd71b15bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db0109b4a900f8cedede0ba291dff5cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_198fe205807a208dc6bd81c375c2b1f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a887d5b03e122662bce479a9659c3274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7aaa2de5ea5e31b58d70ebaaf86b72b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab7b7e4896a61e0a2f056263d058a8e5
publicationDate 2011-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102227422-A
titleOfInvention Heterocyclic JAK Kinase Inhibitors
abstract The present invention relates to compounds of formula (I): and their salts, pharmaceutical compositions, methods of use and methods of preparing them. These compounds provide for the treatment of myeloproliferative disorders and cancer.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112574201-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111494386-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106349224-A
priorityDate 2008-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008005538-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007049041-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421113549
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20745813
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412332542
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421106937
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414688023
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87359371
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58367446
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58398885
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424443244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424320547
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466531892
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45275367
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58367398
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420322167
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58398877
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57654277
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424897569

Total number of triples: 51.